Syon Capital LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Syon Capital LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 111.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 64,444 shares of the biopharmaceutical company's stock after acquiring an additional 33,961 shares during the quarter. Syon Capital LLC's holdings in Pfizer were worth $1,855,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. increased its stake in shares of Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company's stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC bought a new position in Pfizer during the 4th quarter worth $255,000. Brookstone Capital Management lifted its holdings in shares of Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company's stock worth $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. lifted its holdings in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company's stock worth $214,000 after buying an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. boosted its position in shares of Pfizer by 75.0% in the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company's stock valued at $5,004,000 after acquiring an additional 74,487 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 3.8 %

PFE stock traded down $1.01 during mid-day trading on Thursday, reaching $25.26. The company's stock had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. The business's 50 day moving average price is $27.01 and its 200 day moving average price is $28.48. The company has a market cap of $143.04 billion, a price-to-earnings ratio of 70.17, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business's quarterly revenue was down 41.3% on a year-over-year basis. During the same period last year, the company posted $1.14 earnings per share. On average, equities research analysts predict that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.65%. Pfizer's dividend payout ratio (DPR) is presently 466.67%.

Wall Street Analyst Weigh In

Several analysts have weighed in on PFE shares. TD Cowen cut shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Finally, Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a "buy" rating and a $36.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and an average target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.